CELSR3: A Potential Drug Target and Biomarker (G1951)

Target Name: CELSR3

NCBI ID: G1951

CELSR3

CELSR3: A Potential Drug Target and Biomarker

CELSR3, also known as CSL-L32, is a protein that is expressed in various tissues of the body, including the brain, heart, and kidneys. It is a member of the CELSR family, which includes several similar proteins that are involved in the regulation of stem cell proliferation and differentiation. The discovery of CELSR3 and its potential functions as a drug target and biomarker makes it an attractive target for researchers to investigate.

The CELSR3 protein is known to play a role in the regulation of stem cell proliferation and differentiation. It is a negative regulator of the TGF-β pathway, which is a well-known pathway that regulates cell growth, differentiation, and inflammation. The TGF-β pathway is involved in the development and maintenance of tissues and organs, and it is also involved in the regulation of stem cell proliferation.

Research has shown that CELSR3 is involved in the regulation of stem cell proliferation and differentiation by preventing the activity of the TGF-β pathway. This is done by interacting with the TGF-β receptor, which is a protein that is involved in the regulation of stem cell proliferation and differentiation. The TGF-β receptor is a transmembrane protein that is involved in the regulation of cell growth, differentiation, and inflammation.

CELSR3 has also been shown to play a role in the regulation of inflammation. It is involved in the regulation of the production of pro-inflammatory cytokines, such as TNF-伪 and IL-1尾, which are involved in the regulation of inflammation. This is done by interacting with the NF-kappa-B signaling pathway, which is a complex signaling pathway that is involved in the regulation of inflammation.

CELSR3 has also been shown to play a role in the regulation of cell death. It is involved in the regulation of apoptosis, which is a process that is involved in the programmed cell death that occurs in the body. This is done by interacting with the p53 signaling pathway, which is a complex signaling pathway that is involved in the regulation of apoptosis.

CELSR3 has also been shown to play a role in the regulation of the blood-brain barrier. The blood-brain barrier is a barrier that separates the brain from the bloodstream, and it is involved in the regulation of the exchange of nutrients, oxygen, and other substances between the brain and the bloodstream. This is done by interacting with the tight junction protein, which is a protein that is involved in the regulation of the blood-brain barrier.

In conclusion, CELSR3 is a protein that is involved in several important processes in the body. It is a negative regulator of the TGF-β pathway, which is involved in the regulation of stem cell proliferation and differentiation. It is also involved in the regulation of stem cell proliferation and differentiation, inflammation, and cell death. These functions make CELSR3 an attractive target for researchers to investigate, and its potential as a drug target and biomarker make it a promising target for the development of new treatments for a variety of diseases.

Protein Name: Cadherin EGF LAG Seven-pass G-type Receptor 3

Functions: Receptor that may have an important role in cell/cell signaling during nervous system formation

The "CELSR3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CELSR3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets